{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T02:38:42Z","timestamp":1778812722667,"version":"3.51.4"},"reference-count":123,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiovascular diseases (CVDs) which consist of ischemic heart disease, stroke, heart failure, peripheral arterial disease, and several other cardiac and vascular conditions are one of the most common causes of death worldwide and often co-occur with diabetes mellitus and lipid disorders which worsens the prognosis and becomes a therapeutic challenge. Due to the increasing number of patients with CVDs, we need to search for new risk factors and pathophysiological changes to create new strategies for preventing, diagnosing, and treating not only CVDs but also comorbidities like diabetes mellitus and lipid disorders. As increasing amount of patients suffering from CVDs, there are many therapies which focus on new molecular targets like proprotein convertase subtilisin\/kexin type 9 (PCSK9), angiopoietin-like protein 3, ATP-citrate lyase, or new technologies such as siRNA in treatment of dyslipidemia or sodium-glucose co-transporter-2 and glucagon-like peptide-1 in treatment of diabetes mellitus. Both SGLT-2 inhibitors and GLP-1 receptor agonists are used in the treatment of diabetes, however, they proved to have a beneficial effect in CVDs as well. Moreover, a significant amount of evidence has shown that exosomes seem to be associated with myocardial ischaemia and that exosome levels correlate with the severity of myocardial injury. In our work, we would like to focus on the above mechanisms. The knowledge of them allows for the appearance of new strategies of treatment among patients with CVDs.<\/jats:p>","DOI":"10.3390\/ijms242316735","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T03:32:03Z","timestamp":1701055923000},"page":"16735","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-9624","authenticated-orcid":false,"given":"Armanda","family":"Wojtasi\u0144ska","sequence":"first","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2773-2733","authenticated-orcid":false,"given":"Joanna","family":"Ku\u0107mierz","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4527-3355","authenticated-orcid":false,"given":"Julita","family":"Tokarek","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-5339","authenticated-orcid":false,"given":"Jill","family":"Dybiec","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rodze\u0144","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-4746","authenticated-orcid":false,"given":"Ewelina","family":"M\u0142ynarska","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/heartjnl-2016-309573","article-title":"Trends in the epidemiology of cardiovascular disease in the UK","volume":"102","author":"Bhatnagar","year":"2016","journal-title":"Heart"},{"key":"ref_2","unstructured":"GBD 2017 Causes of Death Collaborators (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736\u20131788."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and beyond","volume":"74","author":"Mensah","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100342","DOI":"10.1016\/j.ajpc.2022.100342","article-title":"Ten things to know about ten cardiovascular disease risk factors\u20142022","volume":"10","author":"Bays","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.58803\/rbes.v2i2.14","article-title":"Recent advances in the Prevention and Treatment of Chemotherapy\u2013induced Cardiotoxicity","volume":"2","author":"Kazemnian","year":"2023","journal-title":"Res. Biotechnol. Environ. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1210\/jc.2018-02304","article-title":"Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants","volume":"104","author":"Tripathy","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","article-title":"Genetics of diabetes mellitus and diabetes complications","volume":"16","author":"Cole","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Provenzano, M., Coppolino, G., De Nicola, L., Serra, R., Garofalo, C., Andreucci, M., and Bolignano, D. (2019). Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00314"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Aygun, S., and Tokgozoglu, L. (2022). Comparison of Current International Guidelines for the Management of Dyslipidemia. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237249"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jclinpath-2019-205910","article-title":"Inherited metabolic disorders and dyslipidaemia","volume":"73","author":"Sulaiman","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio, E., Gao, P., Pennells, L., Kaptoge, S., Caslake, M., Thompson, A., Butterworth, A.S., Sarwar, N., and Wormser, D. (2012). Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA, 307, 2499\u20132506."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1210\/endrev\/bnab037","article-title":"A Modern Approach to Dyslipidemia","volume":"43","author":"Berberich","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108172","DOI":"10.1016\/j.pharmthera.2022.108172","article-title":"Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl\/eicosapentaenoic acid","volume":"237","author":"Chapman","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40292-022-00507-8","article-title":"Hypertension and Dyslipidemia Combined Therapeutic Approaches","volume":"29","author":"Borghi","year":"2022","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca-2018-0072","article-title":"Alirocumab for low-density lipoprotein cholesterol lowering","volume":"15","author":"Roth","year":"2019","journal-title":"Future Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/17512433.2017.1318063","article-title":"Alirocumab for the treatment of hypercholesterolaemia","volume":"10","author":"Bozzetto","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"(2015). Alirocumab (Praluent) to Lower LDL-Cholesterol. JAMA, 314, 1284\u20131285.","DOI":"10.1001\/jama.2015.11372"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Huang, H.-C., Hsu, S.-J., Chang, C.-C., Chuang, C.-L., Hou, M.-C., and Lee, F.-Y. (2022). Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137378"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: Prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Steg","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40256-015-0153-0","article-title":"Evolocumab: A Review in Hyperlipidemia","volume":"16","author":"Keating","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11883-018-0720-3","article-title":"Evolocumab: Considerations for the Management of Hyperlipidemia","volume":"20","author":"Wiggins","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hamilton, P. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. Ann. Clin. Biochem., 54.","DOI":"10.1177\/0004563217705053"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hirai, K., Imamura, S., Hirai, A., Ookawara, S., and Morishita, Y. (2020). Effect of Evolocumab on Vulnerable Coronary Plaques: A Serial Coronary Computed Tomography Angiography Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103338"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MOL.0000000000000600","article-title":"New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk","volume":"30","author":"Kersten","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12944-018-0659-y","article-title":"New Insights into ANGPLT3 in Controlling Lipoprotein Metabolism and Risk of Cardiovascular Diseases","volume":"17","author":"Su","year":"2018","journal-title":"Lipids Health Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","article-title":"Protein Region Important for Regulation of Lipid Metabolism in Angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo","volume":"278","author":"Ono","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MOL.0000000000000679","article-title":"The next generation of triglyceride-lowering drugs: Will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?","volume":"31","author":"Reeskamp","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_35","first-page":"49","article-title":"Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia","volume":"14","author":"Kosmas","year":"2022","journal-title":"Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11883-022-01071-1","article-title":"ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis","volume":"24","author":"Mohamed","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects with High and Severe Hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: Effects on lipoprotein metabolism and atherosclerosis","volume":"30","author":"Burke","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am. Heart J."},{"key":"ref_42","first-page":"1","article-title":"Bempedoic acid for the treatment of dyslipidemia","volume":"9","author":"Marrs","year":"2020","journal-title":"Drugs Context"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of Bempedoic Acid in Clinical Practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/fca-2020-0016","article-title":"Bempedoic acid: A promising novel agent for LDL-C lowering","volume":"16","author":"Agarwala","year":"2020","journal-title":"Futur. Cardiol."},{"key":"ref_45","unstructured":"National Institute for Health and Care Exellence (2023, September 01). Icosapent Ethyl with Statin Therapy for Reducing the Risk of CardiovascularEvents in People with Raised Triglycerides. Technology Appraisal Guidance. Available online: https:\/\/www.nice.org.uk\/guidance\/ta805."},{"key":"ref_46","unstructured":"European Medicines Agency (2023, September 01). Vazkepa International Non-Proprietary Name: Icosapent Ethyl. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vazkepa-epar-public-assessment-report_en.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.33963\/KP.a2023.0030","article-title":"PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives","volume":"81","author":"Nicholls","year":"2023","journal-title":"Kardiologia Polska"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.10.013","article-title":"Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers","volume":"81","author":"Laffin","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","first-page":"745","article-title":"Le m\u00e9dicament du mois. L\u2019inclisiran (Leqvio\u00ae), hypocholest\u00e9rol\u00e9miant puissant inhibant la synth\u00e8se de PCSK9 par la technique innovante de l\u2019ARN interf\u00e9rent [Inclisiran (Leqvio\u00ae), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]","volume":"77","author":"Scheen","year":"2022","journal-title":"Rev. Med. Liege"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zhang, M.M., Bahal, R., Rasmussen, T.P., Manautou, J.E., and Zhong, X.B. (2021). The growth of siRNA-based therapeutics: Updated clinical studies. Biochem. Pharmacol., 189.","DOI":"10.1016\/j.bcp.2021.114432"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA Interference: Biology, Mechanism, and Applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dec, A., Niemiec, A., Wojciechowska, E., Malig\u0142\u00f3wka, M., Bu\u0142dak, \u0141., Bo\u0142dys, A., and Okopie\u0144, B. (2023). Inclisiran\u2014A Revolutionary Addition to a Cholesterol-Lowering Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076858"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: Discovery, pharmacology and clinical development\u2014An introductory review","volume":"180","author":"Ranasinghe","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_56","unstructured":"Padda, I.S., Mahtani, A.U., and Parmar, M. (2023). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_57","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2000). Endotext [Internet], MDText.com, Inc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"860196","DOI":"10.3389\/fcvm.2022.860196","article-title":"Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_59","first-page":"461","article-title":"Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians\u2014A population with the highest risk of premature coronary artery disease & diabetes","volume":"138","author":"Enas","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_60","first-page":"569","article-title":"Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts\u2019 opinion. The compromise between EBM and possibilities in healthcare","volume":"18","author":"Banach","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Katsiki, N., Vrablik, M., Banach, M., and Gouni-Berthold, I. (2023). Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals, 16.","DOI":"10.3390\/ph16040577"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","article-title":"Aptamers: Problems, solutions and prospects","volume":"5","author":"Lakhin","year":"2013","journal-title":"Acta Naturae"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Klapak, D., Broadfoot, S., Penner, G., Singh, A., and Inapuri, E. (2018). Development of novel aptamers for low-density lipoprotein particle quantification. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205460"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Komarova, N., Panova, O., Titov, A., and Kuznetsov, A. (2022). Aptamers Targeting Cardiac Biomarkers as an Analytical Tool for the Diagnostics of Cardiovascular Diseases: A Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051085"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1093\/eurheartj\/ehac463","article-title":"Small non-coding RNA therapeutics for cardiovascular disease","volume":"43","author":"Shah","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2022.12.001","article-title":"Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects","volume":"17","author":"Lesogor","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics\u20142020 Update: A Report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"108859","DOI":"10.1016\/j.diabres.2021.108859","article-title":"Microvascular disease and cardiovascular outcomes among individuals with type 2 diabetes","volume":"176","author":"Kaze","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cjca.2021.02.009","article-title":"Cardiovascular Risk Factors and Prevention: A Perspective from Developing Countries","volume":"37","author":"Teo","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.2337\/dc07-0264","article-title":"Diabetic Retinopathy and the Risk of Coronary Heart Disease","volume":"30","author":"Cheung","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.jacc.2019.03.002","article-title":"Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes","volume":"73","author":"Verma","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 diabetes mellitus and cardiovascular disease","volume":"14","author":"Henning","year":"2018","journal-title":"Futur. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Khalid, M., Petroianu, G., and Adem, A. (2022). Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules, 12.","DOI":"10.3390\/biom12040542"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3818196","DOI":"10.1155\/2020\/3818196","article-title":"Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects","volume":"2020","author":"Perrone","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"Heerspink","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 Inhibitors: Physiology and Pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: An update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hell. J. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2017.07.005","article-title":"Protein aggregation, cardiovascular diseases, and exercise training: Where do we stand?","volume":"40","author":"Gouveia","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1074\/jbc.RA119.007585","article-title":"Disruption of valosin-containing protein activity causes cardiomyopathy and reveals pleiotropic functions in cardiac homeostasis","volume":"294","author":"Brody","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sun, X., and Qiu, H. (2020). Valosin-Containing Protein, a Calcium-Associated ATPase Protein, in Endoplasmic Reticulum and Mitochondrial Function and Its Implications for Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113842"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yjmcc.2015.12.020","article-title":"Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus","volume":"91","author":"Lejay","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: A neglected therapeutic target","volume":"123","author":"Hausenloy","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.2011","article-title":"Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis","volume":"15","author":"Eltzschig","year":"2009","journal-title":"Nat. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/HCO.0000000000000447","article-title":"Protecting the heart from ischemia\/reperfusion injury","volume":"32","author":"Donato","year":"2017","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1006\/jmcc.2001.1462","article-title":"Cardioprotective Function of Inducible Nitric Oxide Synthase and Role of Nitric Oxide in Myocardial Ischemia and Preconditioning: An Overview of a Decade of Research","volume":"33","author":"Bolli","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8364848","article-title":"The Dual Role of Inducible Nitric Oxide Synthase in Myocardial Ischemia\/Reperfusion Injury: Friend or Foe?","volume":"2018","author":"Yu","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"46324","DOI":"10.1038\/srep46324","article-title":"The valosin-containing protein is a novel mediator of mitochondrial respiration and cell survival in the heart in vivo","volume":"7","author":"Lizano","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cvr\/cvt136","article-title":"The valosin-containing protein promotes cardiac survival through the inducible isoform of nitric oxide synthase","volume":"99","author":"Lizano","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-1-4939-7598-3_21","article-title":"Studying the role of AMPK in cardiac hypertrophy and protein synthesis","volume":"1732","author":"Mailleux","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cvr\/cvx211","article-title":"Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology","volume":"114","author":"Sluijter","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1530\/JOE-15-0201","article-title":"Microvesicles and exo somes: New players in metabolic and cardiovascular disease","volume":"228","author":"Lawson","year":"2016","journal-title":"J. Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/CIRCGENETICS.110.958975","article-title":"Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients with Cardiovascular Disease Indicate Myocardial Damage","volume":"4","author":"Kuwabara","year":"2011","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1074\/mcp.M115.055731","article-title":"Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury","volume":"15","author":"Cheow","year":"2016","journal-title":"Mol. Cell. Proteom."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.495","article-title":"MicroRNAs in heart failure: From biomarker to target for therapy","volume":"18","author":"Vegter","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1600-6143.2011.03790.x","article-title":"Microvesicles as novel bio markers and therapeutic targets in transplantation medicine","volume":"12","author":"Fleissner","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1152\/ajpheart.00602.2017","article-title":"Myocardial infarc tion-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure","volume":"314","author":"Tian","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"H3052","DOI":"10.1152\/ajpheart.01355.2006","article-title":"HSP60 trafficking in adult cardiac myocytes: Role of the exosomal pathway","volume":"292","author":"Gupta","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/eurjhf\/hfr155","article-title":"Serum levels of microRNAs in patients with heart failure","volume":"14","author":"Goren","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ. Res."},{"key":"ref_115","first-page":"1184","article-title":"Potential role of exosomes in the pathophysiology, diagnosis, and treatment of hypoxic diseases","volume":"11","author":"Duan","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCRESAHA.118.313573","article-title":"Stimulating Cardiogenesis as a Treatment for Heart Failure","volume":"124","author":"Heallen","year":"2019","journal-title":"Circ. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/sctm.17-0196","article-title":"Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future","volume":"7","author":"Tang","year":"2018","journal-title":"STEM CELLS Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.ymthe.2018.04.024","article-title":"Exosomes in Myocardial Repair: Advances and Challenges in the Development of Next-Generation Therapeutics","volume":"26","author":"Adamiak","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.coph.2016.01.003","article-title":"Stem cells and exosomes in cardiac repair","volume":"27","author":"Singla","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/ten.teb.2014.0300","article-title":"Emerging roles for extra cellular vesicles in tissue engineering and regenerative medicine","volume":"21","author":"Lamichhane","year":"2015","journal-title":"Tissue Eng. Part B Rev."},{"key":"ref_121","first-page":"60","article-title":"Extracellular vesicles, exosomes and shedding vesicles in regenerative medicine\u2014A new paradigm for tissue repair","volume":"6","author":"Kim","year":"2017","journal-title":"Biomater. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.7150\/thno.28021","article-title":"Hypoxia-elicited mesenchymal stem cell-derived exosomes facilitates cardiac repair through miR-125b-mediated prevention of cell death in myocardial infarction","volume":"8","author":"Zhu","year":"2018","journal-title":"Theranostics"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.scr.2009.12.003","article-title":"Exosome secreted by MSC re duces myocardial ischemia\/reperfusion injury","volume":"4","author":"Lai","year":"2010","journal-title":"Stem Cell Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16735\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:29:53Z","timestamp":1760131793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/23\/16735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":123,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ijms242316735"],"URL":"https:\/\/doi.org\/10.3390\/ijms242316735","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}